Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Last updated: 2026-11-19 02:54:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Savara Inc. (SVRA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.74, with a market capitalization of $985.08M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.13 to $7.01. This page covers its latest market performance, valuation, price trends and company information.
$985.08M | |
$4.65 | |
$4.91 | |
$4.56 | |
$4.48 | |
4.89M | |
2.37M | |
-- | |
$7.01 | |
$4.13 | |
-- | |
2026-09-30 |
Savara Inc. (SVRA) last closed at $4.74 as of 2026-11-19 00:58:00, up 5.69% ($0.25) from the previous close of $4.48.
During the latest regular trading session, SVRA traded between $4.56 and $4.91, with a volume of 4.89M shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Savara Inc. (SVRA) moved from $5.05 to $4.74, representing a decline of 6.24% ($0.31).
The stock traded between $4.35 and $5.21 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 3.94 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 21.0%
SVRA is currently trading at $4.74, placing it 21.0% of the way from its 52-week low of $4.13 to its 52-week high of $7.01. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 70 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Savara Inc. and SVRA stock.
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
HC Wainwright & Co. analyst Matthew Caufield assumes Savara (NASDAQ:SVRA) with a Buy rating and announces Price Target of $10.
Eligible investors can buy real shares of Savara Inc. (SVRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to SVRA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between SVRA shares and USD.
SVRA Shares to USD
1.00 SVRA shares = 4.735 USD
Calculations are estimates based on the latest available price and are for reference only.